A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Authors
Category Primary study
Registry of TrialsClinical Trials Information System
Year 2024
This article has no abstract
Epistemonikos ID: 0484c5159a9a3f053150f7cc39f04e1512a33636
First added on: Mar 21, 2025